CHAPTER 1 - MARKET SUMMARY
Market Overview
The Vietnam Animal Health Market combines recurring preventive purchases with disease-driven treatment demand across livestock, aquaculture and companion animals. The supplied 2024 sizing basis identifies approximately 115 active licensed operators. Commercial value is measured at the first domestic sale, making importer and manufacturer execution central to market access while preventing repeated counting of downstream product resale.
Southern Vietnam provides an important commercial and production corridor, linking Ho Chi Minh City distributors with livestock customers and Mekong Delta aquaculture. The national aquaculture anchor in the supplied model is 5.45 million tonnes for 2024. Can Tho-based manufacturing and technical distribution support farm access, although this report does not assign unsupported provincial revenue shares.
Market Value
USD 380 Mn
2025, Vietnam
Dominant Region
Southern Vietnam production and distribution corridor
2025, qualitative assessment
Dominant Segment
Veterinary Vaccines; fastest-growing end-user opportunity: Companion Animal Owners
2025, modeled assessment
Total Number of Players
115
2024 supplied universe, carried into the 2025 assessment
Future Outlook
The Vietnam Animal Health Market is projected to reach USD 552 Mn by 2032, compared with USD 380 Mn in 2025 and USD 524 Mn in 2031. Forecast CAGR is 5.50% (2025-2032), following an estimated historical CAGR of 6.29% (2020-2025). The outlook carries forward the supplied market model rather than replacing its sizing basis. Expansion depends on preventive purchasing, aquaculture disease management and formal veterinary channels. Producers with technical field teams can capture recurring accounts, while distributors must balance wider coverage against inventory expiry, receivables and cold-chain requirements. Market access execution remains as important as portfolio breadth.
Aggregate volume is modeled to expand at a CAGR of 4.50% (2025-2032), while the residual price-and-mix index grows at a CAGR of 0.96% (2025-2032). Their multiplicative relationship reconciles to the 5.50% value CAGR (2025-2032). This implies that most expansion comes from usage rather than broad price inflation. Higher-value products can outperform through demonstrated disease prevention, diagnostic support and dependable supply. Companion animal care offers premium positioning, but a smaller starting base limits its immediate contribution. Manufacturers should prioritize repeatable account economics and measured treatment outcomes before committing to extensive local capacity or nationwide exclusivity agreements.
5.50%
Forecast CAGR
USD 552 Mn
2032 Projection
Base Year
2025
Historical Period
2020-2025
Forecast Period
2025-2032
Historical CAGR
6.29% (2020-2025)
CHAPTER 2 - SCOPE OF REPORT
Scope of the Market
CHAPTER 3 - Key Stakeholders
Key Target Audience
Key stakeholders who can benefit from this market analysis for investment, strategy and operational planning.
Investors
5.50% CAGR (2025-2032), cash conversion, registration costs, portfolio risk
Corporates
species exposure, procurement costs, channel productivity, product differentiation
Government
disease surveillance, antimicrobial stewardship, domestic supply, product compliance
Operators
cold-chain integrity, expiry control, reorder frequency, technical coverage
Financial institutions
receivables quality, inventory security, repayment capacity, demand resilience
CHAPTER 4 - Market Size & Growth
Market Size, Growth Forecast and Trends
This section evaluates the historical market size, analyzes year-over-year growth dynamics, and presents forecast projections supported by market performance indicators and demand-side drivers. Historical estimates and projections use the supplied 2024 market anchor. Market values are rounded to whole USD Mn; rates are calculated before rounding.
Historical & Projected Market Size ($ Million)
Year-over-Year Growth Rate (%)
Market Value vs Volume Growth (%)
Historical Market Performance
Historical CAGR is estimated at 6.29% (2020-2025), with the modeled recovery accelerating through 2023 before moderating in the base year. The historical series represents a reconstructed commercial trajectory, not an official statistical release. Estimated annual growth peaks at 6.98% in 2023, reflecting recovery in formal purchasing and disease-management activity. The volume series is backcast from the supplied index using a consistent 4.50% annual assumption. A residual price-and-mix index reconciles volume with value, preserving the distinction between more products purchased and a higher-value product basket. Disease shocks can change both herd demand and emergency purchasing.
Forecast Market Outlook
Forecast CAGR remains 5.50% (2025-2032), preserving the supplied base-case growth assumption beyond its original projection endpoint. The annual absolute revenue increment rises from approximately USD 21 Mn in the first forecast step to USD 29 Mn in the final step. Volume CAGR of 4.50% (2025-2032) explains most expansion, with price-and-mix CAGR of 0.96% (2025-2032) providing the balance. The forecast assumes stable scope, continuing formal-channel access and no major discontinuity in disease control. Procurement quality, cold-chain reliability and customer retention determine which suppliers translate market expansion into sustainable cash generation.
CHAPTER 5 - Market Data
Market Breakdown
The market's growth trajectory is primarily usage-led. The following operating indices distinguish underlying demand expansion from price and product-mix effects, helping investors assess revenue quality.
Year | Market Size (USD Mn) | YoY Growth (%) | Volume Index (2024=100) | Price-and-Mix Index (2024=100) | Value Index (2024=100) | Period |
|---|---|---|---|---|---|---|
| 2020 | $280 Mn | +Baseline | 83.86 | 92.75 | Forecast | |
| 2021 | $296 Mn | +5.71 | 87.63 | 93.83 | Forecast | |
| 2022 | $315 Mn | +6.42 | 91.57 | 95.55 | Forecast | |
| 2023 | $337 Mn | +6.98 | 95.69 | 97.82 | Forecast | |
| 2024 | $360 Mn | +6.82 | 100.00 | 100.00 | Forecast | |
| 2025 | $380 Mn | +5.50 | 104.50 | 100.96 | Forecast | |
| 2026F | $401 Mn | +5.50 | 109.20 | 101.92 | Forecast | |
| 2027F | $423 Mn | +5.50 | 114.12 | 102.90 | Forecast | |
| 2028F | $446 Mn | +5.50 | 119.25 | 103.88 | Forecast | |
| 2029F | $471 Mn | +5.50 | 124.62 | 104.88 | Forecast | |
| 2030F | $496 Mn | +5.50 | 130.23 | 105.88 | Forecast | |
| 2031F | $524 Mn | +5.50 | 136.09 | 106.89 | Forecast | |
| 2032F | $552 Mn | +5.50 | 142.21 | 107.92 | Forecast |
Volume Index
142.21 (2032F, Vietnam). Inventory capacity should follow recurring customer usage rather than shipment targets. Separately, national aquaculture production increased 4.0% in 2024, illustrating the operating activity that supports animal-health consumption. This published production statistic is contextual and does not replace the supplied sizing anchor.
Price-and-Mix Index
107.92 (2032F, Vietnam). Modest aggregate uplift favors differentiated prevention and diagnostic products over blanket price increases. Two domestic ASF vaccines had already received licenses by February 2023, demonstrating that portfolio innovation is an existing competitive mechanism rather than an entirely future event.
Value Index
153.47 (2032F, Vietnam). Commercial expansion requires stronger working-capital control alongside account acquisition. An independently documented shipment of 120,000 Vietnamese ASF vaccine doses to Indonesia in June 2025 demonstrates domestic manufacturing capability; export revenue itself remains outside this report's domestic-market scope.
CHAPTER 6 - Segmentation
Market Segmentation Framework
Seven dimensions organize the same domestic revenue pool into product, delivery, buyer, disease, channel, technology and operating-model views. These are alternative analytical cuts and must not be added together.
No of Segments
7
Dominant Segment
Product Type
Fastest Growing Segment
End User
Product Type
Care Setting
End User
Disease Area
Sales Channel
Technology
Operating Model
Key Segmentation Takeaways
Comprehensive analysis across all extracted segmentation dimensions provides insights into market structure, customer purchasing and distribution patterns. Aquaculture and companion animal products are assigned to their appropriate product categories and separately analyzed by End User, avoiding double counting across overlapping labels in the supplied preliminary taxonomy.
Product Type
is the principal commercial lens, with Veterinary Vaccines representing the leading preventive category in the supplied assessment. Vaccination schedules support repeat purchasing and technical account relationships. Buyers assess product suitability, disease coverage, handling requirements and reliable replenishment. Imported and domestic products compete through evidence, availability and support. No unsupported category-share allocation is imposed on the total market.
End User
captures the strongest demand differentiation, with Companion Animal Owners identified as the fastest-growing opportunity in the supplied qualitative assessment. Clinic-based purchasing supports preventive packages and branded parasiticides. Livestock Producers retain greater absolute scale, while Aquaculture Producers require species-specific disease management. This designation identifies the growth pocket within a dimension, rather than implying different total growth for alternative market cuts.
CHAPTER 7 - Regional Analysis
Regional Analysis
Vietnam is compared with Indonesia, Thailand, the Philippines and Malaysia using a common domestic animal-health product lens. Peer market values are indicative planning estimates, not published harmonized statistics. Disease exposure and veterinary-import trade frameworks provide context for differing commercial conditions.
Ranking among Selected Peer Countries by Estimated Market Size (2025)
4th of 5
Vietnam Market Size (2025)
USD 380 Mn
Vietnam CAGR (2025-2032)
5.50%
Ranking among Selected Peer Countries by Estimated Market Size (2025)
4th of 5
Vietnam Market Size (2025)
USD 380 Mn
Vietnam CAGR (2025-2032)
5.50%
Regional Analysis (Current Year)
Regional Analysis Comparison
| Metric | Vietnam | Indonesia | Thailand | Philippines | Malaysia |
|---|---|---|---|---|---|
| Market Size (USD Mn, 2025; 2032F) | 380; 552 | 630; 1,080 | 520; 780 | 410; 650 | 240; 360 |
| CAGR (%, 2025-2032) | 5.50% (2025-2032) | 8.00% (2025-2032) | 5.96% (2025-2032) | 6.80% (2025-2032) | 5.96% (2025-2032) |
Market Position
Vietnam ranks fourth in this five-country planning comparison at USD 380 Mn in 2025. Its established domestic vaccine sector supports market depth; the ranking derives from report estimates.
Growth Advantage
Vietnam's modeled CAGR of 5.50% (2025-2032) trails Indonesia's 8.00% and the Philippines' 6.80% (2025-2032). Shared disease exposure supports prevention demand but does not determine commercial growth alone.
Competitive Strengths
Vietnam combines commercial ASF vaccine capability, a domestic manufacturing base dating to 1955 and RCEP participation since 2022. These support sourcing flexibility, technical development and regional supply connectivity.
CHAPTER 8 - INDUSTRY ANALYSIS
Growth Drivers, Challenges & Opportunities
Comprehensive analysis of key factors shaping the Vietnam Animal Health Market, including growth catalysts, operational challenges and emerging opportunities across production, distribution and customer segments.
Growth Drivers
Biosecurity-Led Herd Recovery
- Commercial vaccine availability: Licenses issued in 2022 and 2023 (Vietnam) established domestic ASF vaccine supply. Manufacturers can develop preventive accounts, subject to approved indications and field suitability.
- Technical account development: A producer established in 1955 (Vietnam) illustrates the depth of local veterinary manufacturing. Established field relationships can reduce adoption friction for appropriately supported products.
- Preventive Portfolio Substitution: The agricultural antimicrobial-resistance plan for 2021-2025 (Vietnam) supports responsible-use practices. Suppliers with preventive and diagnostic portfolios can participate in changing expenditure patterns rather than relying exclusively on antimicrobial sales.
Aquaculture Disease Management
- Export-linked purchasing: Seafood exports reached approximately USD 10,000 Mn (2024, Vietnam), strengthening incentives to protect output quality and continuity. Qualified health-product suppliers benefit when farms formalize purchasing.
- Species-specific portfolios: Shrimp exports represented approximately USD 4,000 Mn (2024, Vietnam). Suppliers need species-specific technical support because products and administration practices do not transfer uniformly between shrimp and finfish.
- Cluster-based distribution: Pangasius exports represented approximately USD 2,000 Mn (2024, Vietnam). Concentrated production relationships favor distributors that combine replenishment with documented disease-management support.
Companion Animal Formalization
- Preventive-care awareness: A campaign targeted approximately 8,500 dogs and cats (2025, Duc Hue). Local partnerships can expand awareness and support future demand for properly administered preventive products.
- Clinical relevance: Rabies causes more than 70 human deaths annually (current country profile, Vietnam). Veterinary prevention has public-health relevance, strengthening the case for coordinated product supply and owner education.
- Established specialist presence: A dedicated local animal-health subsidiary dates to 1997 (Vietnam). Existing branded portfolios and clinic relationships support formal purchasing, while entrants need differentiated products and veterinary engagement.
Market Challenges
Disease-Driven Demand Volatility
- Customer solvency: Regional herd disruption remains material: Philippine swine inventory declined 8.5% year on year at December 2024. Similar disease-linked shocks can weaken buyer liquidity and distributor collections.
- Inventory planning: Thailand publicly confirmed ASF in 2022, demonstrating that disease exposure can change even in established production markets. Importers need flexible replenishment and expiry-sensitive stock allocation.
- Product Suitability and Field Performance: Veterinary-drug management under Circular 13/2016/TT-BNNPTNT (Vietnam) makes approved indications central to commercialization. Suppliers should avoid extrapolating efficacy across species, disease strains or unsupported uses.
Registration and Administrative Execution
- Responsibility mapping: The administrative notice identified 28 procedures affected by decentralization (2025, Vietnam). Importers must assign responsibility across product registration, local operating permissions and dossier maintenance.
- Local technical capability: HANVET records northern manufacturing GMP certification in 2008 (Vietnam). Manufacturing credentials and quality systems require operational investment and should be evaluated separately from sales coverage.
- Trade does not replace authorization: EVFTA has applied since 1 August 2020, but preferential customs treatment and veterinary authorization remain distinct processes. Commercial teams need compliant origin documentation and product-specific market access.
Antimicrobial Portfolio Transition
- Revenue exposure: Decision 3609/QD-BNN-TY (2021, Vietnam) emphasizes antimicrobial management. Suppliers should map exposure by approved use and customer practice rather than assume uniform growth across therapeutic categories.
- Evidence requirements: Vietnam's veterinary-drug framework dates to 2016 and has subsequent amendments. Product positioning must follow authorized claims, making technical evidence and regulatory maintenance recurring commercial costs.
- Channel Working Capital: RCEP entered into force for Vietnam in 2022, widening regional sourcing options. Additional suppliers can intensify inventory competition, requiring disciplined credit limits and product-level cash-conversion tracking.
Market Opportunities
Preventive Health Account Programs
- Commercialization milestones in 2022 and 2023 (Vietnam) support account programs combining eligible vaccines with separately priced diagnostic consumables. Contracts should retain transparent product pricing and approved-use boundaries.
- Beneficiaries: A 120,000-dose export shipment in June 2025 illustrates manufacturing readiness. Domestic customers can benefit from qualified local supply, while investors can assess partnerships without counting export sales in domestic demand.
- Execution requirement: The official 2025 account describes continuing evaluation for additional animal groups. Expansion must follow supporting evidence and applicable approvals rather than assuming every production stage is immediately addressable.
Species-Specific Aquaculture Solutions
- Shrimp export growth of 16.7% (2024, Vietnam) supports focused health-product programs. Revenue should be tied to registered products and repeat farm purchasing rather than unsupported promises of production gains.
- Beneficiaries: Pangasius export growth of 9.6% (2024, Vietnam) supports specialized producer relationships. Manufacturers and distributors can differentiate through species knowledge, local availability and documented technical service.
- Traceable Diagnostic Consumables: Aquaculture production expanded 4.0% in 2024 (Vietnam). Better sample handling and documented disease identification can support appropriate product selection, provided laboratories and field teams use validated methods.
Clinic-Based Preventive Portfolios
- Community vaccination activity running since 2021 (Long An) illustrates repeat preventive engagement. Clinics can develop product-based vaccination and parasite-control schedules while consultation revenue remains outside this market definition.
- Beneficiaries: Virbac Vietnam was established in 1997, demonstrating an existing specialist supplier base. Clinics and manufacturers can improve continuity through authenticated procurement, stock availability and owner reminders.
- Execution requirement: Dogs account for up to 99% of human rabies transmission cases globally. Commercial expansion should combine appropriate animal prevention with education and compliant administration, supporting measurable public-health relevance.
CHAPTER 9 - Competitive Landscape
Competitive Landscape Overview
Competition combines multinational preventive portfolios with established domestic manufacturing. Registration, quality systems, technical support and distributor execution create barriers, while the supplied company universe indicates a fragmented market beyond leading suppliers.
Market Share Distribution
Top 5 Players
Market Dynamics
8 new entrants in the past 5 years, indicating strong market attractiveness and growth potential.
Company Name | Market Share | Headquarters | Founding Year | Core Market Focus |
|---|---|---|---|---|
Boehringer Ingelheim Vietnam | - | Ho Chi Minh City, Vietnam (local office) | - | Livestock and companion animal preventive portfolios. |
Zoetis Vietnam | - | Ho Chi Minh City, Vietnam (local office) | - | Livestock, companion animal and aquaculture health products. |
NAVETCO | - | Ho Chi Minh City, Vietnam | 1955 | Domestic veterinary vaccines, medicines and aquaculture health products. |
MSD Animal Health Vietnam | - | Ho Chi Minh City, Vietnam (local office) | - | Vaccines, veterinary medicines and species-specific health portfolios. |
Elanco Vietnam | - | - | - | Veterinary pharmaceuticals, companion animal products and aquaculture health solutions. |
Vemedim Corporation | - | Can Tho, Vietnam | 1992 | Livestock, aquaculture and companion animal pharmaceuticals and supplements. |
Virbac Vietnam | - | - | 1997 | Companion animal medicines and livestock and aquaculture health products. |
Huvepharma Vietnam | - | Sofia, Bulgaria (group headquarters) | - | Veterinary pharmaceuticals and biologicals; commodity nutrition excluded from scope. |
HANVET | - | - | 1988 | Veterinary pharmaceuticals, vaccines and aquaculture medicines. |
Ceva Sante Animale Vietnam | - | Ho Chi Minh City, Vietnam (local office) | 2008 | Poultry and swine vaccines and veterinary pharmaceuticals. |
Cross Comparison Parameters
The report provides detailed cross-comparison of key players across 10 performance parameters to identify competitive strengths and weaknesses.
Registered Veterinary Product Portfolio
Active Veterinary Distribution Coverage
Vietnam Animal Health Revenue Growth
Vietnam Animal Health Gross Margin
Analysis Covered
Market Share Analysis:
Assess domestic revenue concentration using comparable product and channel definitions.
Cross Comparison Matrix:
Compare registered portfolios, distribution coverage, revenue growth and gross margins.
SWOT Analysis:
Evaluate technical strengths, registration dependencies, portfolio gaps and competitive threats.
Pricing Strategy Analysis:
Benchmark treatment economics, distributor discounts, tender terms and premium positioning.
Company Profiles:
Examine local presence, manufacturing capabilities, species focus and commercialization priorities.
CHAPTER 10 - REPORT TOC
Table of Contents
Market Assessment Phase
Supply-side and competitive intelligence covering market sizing, segmentation, competitive dynamics, regulatory landscape, and future forecasts.
Go-To-Market Strategy Phase
15 chapters
Entry strategy evaluation, execution roadmap, partner recommendations, and profitability outlook.
Survey Phase
8 chapters
Demand-side primary research conducted through structured interviews and online surveys with end users across priority metros and Tier 2/3 cities to capture consumption behavior, unmet needs, and purchase drivers.
Complete Report Coverage
201+ detailed sections covering every aspect of the market
143
Assessment Sections
58
Strategy Sections
CHAPTER 11 - Our Approach
Research Methodology
Desk Research
- Review veterinary product registration requirements.
- Map domestic vaccine manufacturing capabilities.
- Assess livestock and aquaculture demand.
- Verify species-specific supplier portfolio presence.
Primary Research
- Proposed interviews with veterinary regulatory directors.
- Proposed interviews with livestock procurement managers.
- Proposed interviews with aquaculture technical managers.
- Proposed interviews with veterinary clinic owners.
Validation and Triangulation
- Plan validation across 250 qualified respondents.
- Reconcile importer sales with manufacturer shipments.
- Separate domestic demand from export revenues.
- Check indices against consistent revenue boundaries.
CHAPTER 12 - FAQ
FAQs
Still have questions?
Our research team is here to help you find the right solution
CHAPTER 13 - Related Research
Explore Related Reports
Expand your market intelligence with complementary research across regions and adjacent markets.
Regional/Country ReportsRelated market analysis across key regions
Related market analysis across key regions
No regional reports found.
Adjacent ReportsRelated markets and complementary research
Related markets and complementary research
- Global Veterinary Vaccines Market Size, Share & Forecast, By Vaccine Technology, Animal Type & Route of Administration, 2026-2031
- Thailand Aquaculture Health Management Market
- Indonesia Veterinary Diagnostics Market Size, Share & Forecast, By Product Type, Animal Type & End User, 2025–2032
- Malaysia Animal Nutrition Market
- Japan Cold Chain Logistics Market Size, Share & Forecast, By Service Type, Mode of Transport & End-Use Industry, 2025–2032
500+
Market Research Reports
50+
Countries Covered
15+
Industry Verticals